385 results on '"Zeiser, Robert"'
Search Results
2. Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome
3. Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial
4. How risky is a second allogeneic stem cell transplantation?
5. 15-year remission in refractory FLT3-mutated AML attained by sorafenib
6. Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial
7. ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?
8. IL-23 stabilizes an effector Treg cell program in the tumor microenvironment
9. Acute Graft-Versus-Host Disease
10. Multiomic spatial landscape of innate immune cells at human central nervous system borders
11. A novel approach to visualize clinical benefit of therapies for chronic graft versus host disease (cGvHD): the probability of being in response (PBR) applied to the REACH3 study
12. Deciphering the role of the major histocompatibility complex, the intestinal microbiome and metabolites in the pathogenesis of acute graft-versus-host disease
13. Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD
14. The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD
15. The role of the MDM2/p53 axis in antitumor immune responses
16. Long-term follow-up of patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation after primary induction failure
17. Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease
18. Mast cell deficiency prevents BCR::ABL1 induced splenomegaly and cytokine elevation in a CML mouse model
19. Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis
20. Granulocyte-Macrophage Colony-Stimulating Factor in Allogenic Hematopoietic Stem Cell Transplantation: From Graft-versus-Host Disease to the Graft-versus-Tumor Effect
21. CSF1R inhibition promotes neuroinflammation and behavioral deficits during graft-versus-host disease in mice
22. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation
23. A personalized, organ-based approach to the treatment of chronic steroid-refractory graft-versus-host disease
24. Phosphoinositide acyl chain saturation drives CD8+ effector T cell signaling and function
25. GPRC5C drives branched-chain amino acid metabolism in leukemogenesis
26. Extracorporeal photopheresis in acute and chronic steroid‑refractory graft-versus-host disease: an evolving treatment landscape
27. Functional characterization of the PI3K/AKT/MTOR signaling pathway for targeted therapy in B-precursor acute lymphoblastic leukemia
28. Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms
29. Reg3α concentrations at day of allogeneic stem cell transplantation predict outcome and correlate with early antibiotic use
30. Therapy response of glucocorticoid-refractory acute GVHD of the lower intestinal tract
31. FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation
32. Contributors
33. Prognostic value of blood biomarkers in steroid-refractory or steroid-dependent acute graft-versus-host disease: a REACH2 analysis
34. Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis Aged 70 Years or Older: A Study from the German Registry for Stem Cell Transplantation
35. Anti–PD-1 cancer immunotherapy induces central nervous system immune-related adverse events by microglia activation
36. Retinoic acid signaling acts as a rheostat to balance Treg function
37. Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation
38. Toward a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force
39. Three US Food and Drug Administration–approved therapies for chronic GVHD
40. Hämatologische und onkologische Notfälle.
41. Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial
42. FDG-PET/CT is a powerful tool to predict and evaluate response to chimeric antigen receptor (CAR) T-cell therapy in Non-Hodgkin-Lymphoma (NHL)
43. Editorial: Transcriptional and epigenetic regulation in normal and aberrant hematopoiesis
44. Coevolving JAK2V617F+relapsed AML and donor T cells with PD-1 blockade after stem cell transplantation: an index case
45. The impact of pulmonary function in patients undergoing autologous stem cell transplantation
46. Flares of Acute Graft-Versus-Host Disease (GVHD): A Mount Sinai Acute GVHD International Consortium (MAGIC) Analysis
47. Effects of Concomitant Azoles on Ruxolitinib Treatment in Patients with Acute Graft-Versus-Host Disease: A Post Hoc Analysis from the Randomized Phase 3 REACH2 Study
48. Effects of Concomitant Azoles on Ruxolitinib Treatment in Patients with Chronic Graft-Versus-Host Disease: A Post Hoc Analysis from the Randomized Phase 3 REACH3 Study
49. The Mount Sinai Acute Gvhd International Consortium (MAGIC) Model: An Integrated Clinical and Biomarker Grading System for Acute Graft-Versus-Host Disease (GVHD)
50. The MAGIC Algorithm Probability Predicts Treatment Response and Long-Term Outcomes to Second-Line Therapy for Acute Gvhd
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.